ArticleSynthetic and systems biotechnology2026
Defense-associated reverse transcriptases define an emerging class of noncanonical DNA-writing systems.
Article in Synthetic and systems biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Defense-associated reverse transcriptases (DRTs) are emerging as a mechanistically diverse class of bacterial antiviral enzymes. Rather than acting simply as RNA-to-DNA copying proteins, they generate a wide range of unconventional DNA products, including de novo gene-assembling cDNAs, random single-stranded DNA, DNA homopolymers, poly(A)-rich cDNAs and protein-templated dinucleotide-repeat DNA. These findings suggest that DRTs are better viewed as DNA-construction modules than as unusual versions of canonical reverse transcriptases. In particular, DRT3 shows how RNA-templated and protein-templated synthesis can be combined within a single defence pathway to generate complementary repeat strands and repeat double-stranded DNA. We argue that this emerging chemistry expands the landscape of prokaryotic reverse transcription and may offer new reaction principles for synthetic biology and nucleic acid engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.